7 October 2021 - Deborah Wilkes
Maxwellia is backing Lovima with a major marketing campaign in the UK, while Bayer Consumer Health has recalled some lots of Lotrimin AF and Tinactin in the US.
Maxwellia’s support for Lovima
Maxwellia has announced a GBP3 million (USD4 million) marketing campaign for its Lovima oral contraceptive in the UK.
The campaign was designed to “educate women about the choice they now have to buy the progestogen-only contraceptive pill without a prescription”, said Maxwellia, adding that it signposted pharmacists as “an important cornerstone in contraceptive health”.
A 30-second television commercial, which made its debut on 6 October 2021 on Channel 4, focuses on the “liberation” of the contraceptive pill from prescription-only status.
In addition to television advertising, the campaign includes public relations activity, point-of-sale material and digital initiatives.
Switch specialist Maxwellia recently launched Lovima in the UK following the decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to allow two oral contraceptive pills – HRA Pharma’s Hana and Lovima – to be sold without a prescription (click here to read the News story).
Hana and Lovima are both supplied as film-coated tablets containing 75 microgram desogestrel.
Bayer recalls selected Lotrimin AF and Tinactin
Bayer Consumer Health has voluntarily recalled certain lots of Lotrimin AF and Tinactin antifungal spray products in the US due to the presence of benzene.
Noting the recall was a “precautionary measure”, Bayer said it had found benzene in some samples of the products.
Bayer stressed that the “levels detected are not expected to cause adverse health consequences in consumers”.
The company noted that benzene, which is classified as a human carcinogen, was not an ingredient in any of Bayer Consumer Health’s products.